Neurophth Secures Nearly 95 Million Usd In Series C+ Financing For Gene Therapy Clinical Trials
Round Type
Series C
WuhanHealth CareInvestors
Description
Neurophth Therapeutics, Inc. ("Neurophth"), a China's leading gene therapy company for ophthalmic diseases, announced the closing of nearly 95 million USD in Series C+ financing. The round was co-led by Yangtze River-CMB International Industry Fund, Wuhan Optical Valley Financial Holding Group, Wuhan Hi-Tech Holding Group, Hubei KTLC and Guangzhou Jinkong Fund. Additionally, several prominent investment firms participated, including CMG-SDIC Capital, Silicon Paradise Asset Management and Yangtze River Industry Fund
Quick answer
Neurophth Therapeutics raised an undisclosed amount in a Series C round, dated August 11, 2023. Investors: Hong Shan, Bohe Angel Fund, Miracle Light Venture, Fosun, Northern Light Venture Capital, Grand Mount Capital, Harvest Capital and Oriza Holdings. Neurophth Therapeutics is based in Wuhan, Hubei, China.
- How much did Neurophth Therapeutics raise?
- Neurophth Therapeutics raised an undisclosed amount in a Series C round on August 11, 2023.
- Who invested in Neurophth Therapeutics?
- Hong Shan, Bohe Angel Fund, Miracle Light Venture, Fosun, Northern Light Venture Capital, Grand Mount Capital, Harvest Capital and Oriza Holdings are named as investors in this round.
- What does Neurophth Therapeutics do?
- We are China’s first gene therapy company for ophthalmic diseases.
- Where is Neurophth Therapeutics based and how big is it?
- Neurophth Therapeutics is based in Wuhan, Hubei, China.
- Who are the decision-makers at Neurophth Therapeutics?
- Fundz holds 1 contact at Neurophth Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Health Care around the same time
Companies in the same sectors as Neurophth Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Acasti raised $7.5M on September 25, 2023.
- Greater Good Healthcare raised $10M on September 25, 2023.
- Qihan Biotech raised an undisclosed amount (Series B) on September 23, 2023.
- Atropos Health raised an undisclosed amount (Funding Round) on September 23, 2023.
- CMR Surgical raised $165M (Funding Round) on September 22, 2023.
- Avalyn raised $189M on September 22, 2023.
Who to call at Neurophth Therapeutics, and when
A new round usually means Neurophth Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Neurophth Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Neurophth Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Neurophth Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Neurophth Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Neurophth Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.